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The Phase II study, designated HPV-003 (NCT01304524),
assessed the safety and efficacy of VGX-3100 in 167
women with biopsy-proven cervical intraepithelial neopla-
sia (CIN) 2 or CIN 3 and HPV-16 or -18. The randomized,
placebo-controlled, double-blind study, was stratified by
age and severity of CIN and evaluated cervical tissue
changes after three 6 mg intramuscular doses of the DNA
vaccine VGX-3100 followed by electroporation (EP) with
Inovio’s CELLECTRA® 2000 device at weeks 0, 4, and 12.
Cervical tissue was examined before starting blinded treat-
ment and ~9 months later. The primary endpoint was
regression of CIN 2 or CIN 3 to CIN 1 or no disease at
6 months post third dose. In the per-protocol population
(PPP), lesions regressed in 53 of the 107 women receiving
VGX-3100 (49.5%) as compared to 11 of the 36 women in
the placebo group (p < 0.025). The secondary endpoint
was to demonstrate HPV-16 or -18 clearance from the
cervix in conjunction with regression of CIN 2/3 to CIN1
or no disease. Among the 107 women in the VGX-3100
group, 43 demonstrated regression and virological
clearance (40.2%), compared to 5 out of 35 (14.3%) in the
placebo group (p < 0.025).
The study also explored cell mediated immune responses
to VGX-3100 in blood samples taken prior to the first
vaccine dose and periodically thereafter. IFN-g ELISpot
results revealed higher responses in the VGX-3100 treated
group than in the placebo group. Flow cytometry and
immunohistochemistry analyses are also ongoing.
Finally, subjects were also monitored for tolerability and
safety. The treatment was generally well-tolerated, with
only administration site redness occurring significantly
more frequently in the VGX-3100 group compared to
the placebo group in the 7- and 28-day periods following
treatment.
Altogether, the successful Phase II results clearly illus-
trate the highly promising potential of therapeutic vaccina-
tion with DNA followed by electroporation for the
treatment of HPV-related precancerous cervical disease in
women as well as HPV-associated cervical, head and neck,
and anogenital cancers.
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